

# Combinations of Psychoplastogens and DYRK1A Inhibitors

Tech ID: 34754 / UC Case 2022-528-0

## ABSTRACT

Researchers at the University of California, Davis have developed a class of compounds intended for the treatment of neurodegenerative diseases such as Alzheimer's by inhibiting DYRK1A kinase and modulating 5-HT2Rs.

## FULL DESCRIPTION

This technology consists of compounds functioning as both inhibitors of the kinase DYRK1A and psychoplastogenic modulators of serotonin 2 receptors (5-HT2Rs). These compounds are considered promising for developing therapeutics to treat neurodegenerative diseases like Alzheimer's. DYRK1A is known to phosphorylate amyloid precursor protein and tau protein, which play a role in the pathophysiology of Alzheimer's, Down Syndrome, and related diseases. Inhibiting DYRK1A activity, along with promoting cortical neuron growth through 5-HT2 modulation has potential for rescuing the cortical atrophy and cognitive impairment observed in conditions like Alzheimer's and Down syndrome.

## APPLICATIONS

- ▶ Treatment of neurodegenerative diseases, particularly Alzheimer's disease.
- ▶ Treatment of Down syndrome.
- ▶ Potential use in the development of a new class of therapeutics for neurodegenerative disorders.

## FEATURES/BENEFITS

- ▶ Inhibits DYRK1A activity, involved in the development of neurodegenerative diseases and Down syndrome.
- ▶ Blocks tau hyperphosphorylation.
- ▶ Promotes cortical neuron growth.
- ▶ Potential synergism between DYRK1A inhibition and 5-HT2Rs for Alzheimer's prevention/treatment.
- ▶ Development and progression of treatments for Alzheimer's and related neurodegenerative diseases.

## PATENT STATUS

Country	Type	Number	Dated	Case
Patent Cooperation Treaty	Reference for National Filings	2024/220485	10/24/2024	2022-528

Patent Pending

## CONTACT

Prabakaran  
 Soundararajan  
[psoundararajan@ucdavis.edu](mailto:psoundararajan@ucdavis.edu)  
 tel: .



## INVENTORS

- ▶ Olson, David E.
- ▶ Warren, Hunter

## OTHER INFORMATION

### KEYWORDS

Alzheimer's disease,  
 Down syndrome,  
 DYRK1A, kinase inhibitor,  
 neurodegenerative  
 diseases,  
 psychoplastogen,  
 serotonin 2 receptor, tau  
 hyperphosphorylation,  
 therapeutics

### CATEGORIZED AS

- ▶ **Biotechnology**
- ▶ Health
- ▶ **Medical**
- ▶ New Chemical Entities, Drug Leads
- ▶ Therapeutics

## ADDITIONAL TECHNOLOGIES BY THESE INVENTORS

- ▶ [Novel Psychoplastogenic Tropanes for Treating Brain Disorders](#)
- ▶ [Iboga Entactogens](#)
- ▶ [dimerLight](#)
- ▶ [Psychoplastogens For Treating Hearing-Related Disorders](#)

**University of California, Davis**

**Technology Transfer Office**

1 Shields Avenue, Mrak Hall 4th Floor,  
Davis, CA 95616

Tel:

530.754.8649

[techtransfer@ucdavis.edu](mailto:techtransfer@ucdavis.edu)

<https://research.ucdavis.edu/technology-transfer/>

Fax:

530.754.7620

© 2026, The Regents of the University of California

[Terms of use](#)

[Privacy Notice](#)